JPRN-UMIN000027432已完成2 期
Afatinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring active EGFR mutations : an open-label, randomized, multicenter, phase II study - Afatinib vs Afatinib+Bevacizumab
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) EGFR exon20 T790M 2) Symptomatic brain metastasis 3) Meningitis 4) Other cancers 5) Hemoptysis 6) Hemorrhagic tendency (coagulation disorder etc.) 7) Invasion to measure artery or vessel 8) Invasion to mucosa of bronchus 9) Pleural effusion, ascites or pericardial effusion requiring drainage 10) With severe complication (SVC symdrome, interstinal neumonia etc.) 11) History of serious drug allergies 12) Pregnancy, breast feeding, or hesitation in contraception 13) Other conditions not suitable for this study
研究者
相似试验
已完成
1 期
Afatinib with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutation:phaseI studyon-small cell lung cancerJPRN-UMIN000015944Okayama Lung Cancer Study Group (OLCSG)24
已完成
1 期
Phase I study of afatinib + bevacizumab for advanced NSCLC with EGFR mutatioon-small cell lung cancerJPRN-UMIN000016029Juntendo University20
已完成
2 期
Afa+Bev for EGFR mutant NSCLCon-squamous non-small cell lung cancerJPRN-jRCTs061180006Kiura Katsuyuki100
进行中（未招募）
1 期
Afatinib and selumetinib in advanced KRAS mutant positive and PIK3CA wildtype non-small cell lung cancer and colorectal cancerPatients with histological or cytological proof of advanced KRAS mutant and PIK3CA wildtype non small cell lung cancer (NSCLC) and colorectal cancer (CRC). In part B: for which first-line treatment failed.MedDRA version: 21.1 Level: PT Classification code 10029520 Term: Non-small cell lung cancer stage IIIA System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10029521 Term: Non-small cell lung cancer stage IIIB System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10029515 Term: Non-small cell lung cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10029518 Term: Non-small cell lung cancer stage II System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001855-22-NLetherlands Cancer Institute- Antoni van Leeuwenhoek Hospital140
进行中（未招募）
1 期
Afatinib in combination with cetuximab in EGFR exon 20 insertion positive non-small-cell lung cancerEGFR exon 20 insertion positive non-small cell lung cancerMedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001521-97-NLStichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis37